A Phase II Study Investigating Cabozantinib in Patients with Refractory Metastatic Colorectal Cancer (AGICC 17CRC01)

PURPOSE: Multi-tyrosine kinase inhibitors (TKI) have shown clinical activity in patients with metastatic colorectal cancer. Cabozantinib, a multi-TKI, exhibited potent antitumor activity superior to regorafenib in preclinical colorectal cancer patient-derived tumor xenograft models. This phase II st...

Descripción completa

Detalles Bibliográficos
Autores principales: Scott, Aaron J., Basu Mallick, Atrayee, Dotan, Efrat, Cohen, Steven J., Gold, Philip J., Hochster, Howard S., Subramaniam, Somasundaram, Barzi, Afsaneh, Watts, George S., Blatchford, Patrick J., Messersmith, Wells A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035393/
https://www.ncbi.nlm.nih.gov/pubmed/36969746
http://dx.doi.org/10.1158/2767-9764.CRC-22-0169

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035393/
https://www.ncbi.nlm.nih.gov/pubmed/36969746
http://dx.doi.org/10.1158/2767-9764.CRC-22-0169

Ejemplares similares